20 février 2024
info:eu-repo/semantics/openAccess
adelage, « USA FDA - Vyjuvek: BLA approval ( Catapult's regulatory round-up May) », ELSIBI, ID : 10.58079/vvd4
The FDA has granted approval for Krystal Biotech’s Vyjuvek (beremagene geperpavec-svdt) to treat dystrophic epidermolysis bullosa (DEB) in patients aged six months and above. Vyjuvek is a non-invasive, topical, re-dosable gene therapy that delivers functional human COL7A1 gene copies to offer wound healing. It is the first re-dosable gene therapy as well as the first and only FDA-approved treatment for both recessive and dominant types of DEB, a rare and serious genetic disease affecting the...